Navigation Links
MAP Pharmaceuticals Announces All Non-Asthmatic Patients Complete Treatment in Open-Label Trial and Completion of Treatment in QT Trial for LEVADEX™ Clinical Program
Date:9/8/2010

MOUNTAIN VIEW, Calif., Sept. 8 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that all non-asthmatic patients and a subset of asthmatic patients have completed 12 months of treatment in the open-label safety trial of LEVADEX™. In addition, the Company has completed patient treatment in a thorough QT trial, the last trial necessary to support a New Drug Application (NDA) for LEVADEX. At this time, all patients have been enrolled in the Company's clinical trials in support of an NDA, which the Company expects to submit in the first half of 2011.  LEVADEX is a novel orally inhaled migraine therapy that has completed Phase 3 efficacy development for the acute treatment of migraine.

The Company also gave an update of its LEVADEX clinical development program:

  • Open-label safety trial: To date, more than 400 patients have completed at least six months of treatment and more than 200 patients have completed twelve months of treatment. All non-asthmatic patients and a subset of asthmatic patients have completed treatment.  The remaining patients are expected to complete treatment in 2010.  The Company and an independent data monitoring committee (DMC) recently completed an interim safety review of all patients, including asthmatics. In this trial, LEVADEX has been well tolerated and no drug-related serious adverse events have been reported. To date, no clinically significant trends have been reported for LEVADEX in the evaluation of cardiovascular measurements (as measured by electrocardiogram, echocardiogram and chest x-ray) and pulmonary function (as measured by DLco and FEV1). This 12 month open-label, long- term safety extension of the Company's Phase 3 FREEDOM-301 trial is designed to evaluate overall safety of LEVADEX in at least 300 patients for six months and 150 patients for 12 months, including asthmatics.
    '/>"/>

  • SOURCE MAP Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related medicine technology :

    1. Transcept Pharmaceuticals to Present at Rodman & Renshaw and Stifel Nicolaus Investor Conferences in September 2010
    2. Cadence Pharmaceuticals to Present at Four Investment Conferences During the Month of September 2010
    3. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
    4. MAP Pharmaceuticals to Present at Upcoming Healthcare and Scientific Conferences
    5. Tibotec Pharmaceuticals Seeks European Marketing Authorization for Investigational Once-Daily HIV Treatment TMC278
    6. Shanghai SynTheAll Pharmaceuticals Co., Ltd. (STA) Receives ISO 14001 Certification
    7. Transdel Pharmaceuticals Presents Phase 3 Study Data on Ketotransdel® at World Pain Congress in Montreal, Canada
    8. Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting
    9. Optimer Pharmaceuticals to Present at September 2010 Investor Conferences
    10. Pfizer to Acquire FoldRx Pharmaceuticals
    11. Reportlinker Adds The Market for Pharmaceuticals in Brazil, Russia, India & China
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/30/2015)... 30, 2015 Vermillion, Inc. (VRML), ... disease, announced today it will report its ... market close on Thursday, August 13, 2015, ... webcast at 4:30pm Eastern.Conference Call and Webcast:  ... Eastern/1:30pm Pacific  Domestic: , 888-430-8691International: ...
    (Date:7/30/2015)... 2015 What can be expected ... are going to grow at the fastest rates? ... to 2025, assessing data, trends, opportunities and prospects there. ... tables, charts, and graphs. Discover the most lucrative areas ... new study lets you assess forecasted sales at overall ...
    (Date:7/30/2015)... 2015  Cleave Biosciences today announced that the ... the company a key patent providing the protection ... This newly issued patent, "Fused pyrimidines ... 9,062,026, allows for claims on the composition of ... inhibitor of p97, a critical enzyme that controls ...
    Breaking Medicine Technology:Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 2Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 3Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 4Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 5Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 6
    ... 2012 Escalon Medical Corp.,s (Nasdaq Market: ESMC) subsidiary, ... successfully completed the outsourced manufacturing of its HbA1c instruments ... sale. Drew has also identified an outsourcing partner for ... available for sale by the summer of 2012.  Drew ...
    ... Pharmaceuticals, Inc. (Nasdaq: LXRX ) announced today ... and chief executive officer, will present at the RBC Healthcare ... 10:30 a.m. Eastern Time.  Dr. Sands will provide an overview ... A live webcast of the presentation will be available through ...
    Cached Medicine Technology:Escalon Announces That the Restructuring of Its IVD Business is Largely Completed 2Escalon Announces That the Restructuring of Its IVD Business is Largely Completed 3Escalon Announces That the Restructuring of Its IVD Business is Largely Completed 4Lexicon Pharmaceuticals to Present at the RBC Healthcare Conference 2
    (Date:7/30/2015)... VA (PRWEB) , ... July 30, 2015 , ... ... introduction of the ‘Mary Jo Lawyer-Spano Mesothelioma Patient Registry Act of 2015’. ... Schakowsky (D-IL), Chris Collins (R-NY), Peter King (R-NY), Betty McCollum (D-MN), Joe Kennedy ...
    (Date:7/30/2015)... ... 30, 2015 , ... Boston Web Marketing is ... Google Partners is the platform for search marketing agencies to communicate with the ... necessary to run successful search marketing campaigns. Google Partners also affords businesses the ...
    (Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... Ocean Hills ... available, including the very rare “no recommendations.” No recommendations means CARF found no areas ... is a notation that less than 3% of all facilities receive. In addition, Ocean ...
    (Date:7/30/2015)... NY (PRWEB) , ... July 30, 2015 , ... ... at Mount Sinai Earns National Cancer Institute Designation , The Tisch Cancer Institute ... a National Cancer Institute (NCI)-designated cancer center. TCI joins an elite group of ...
    (Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... 1Heart Caregiver ... 2015 - “Learn How to Make Money in the Booming Homecare Business.” This will ... CA 90010. , The event will be hosted by 1Heart’s very ...
    Breaking Medicine News(10 mins):Health News:Bill to Create Patient Registry for Deadly Cancer Introduced in Congress 2Health News:Boston Web Marketing Attends Google Partners All-Stars Summit 2Health News:Ocean Hills Recovery Receives Accreditation from CARF International 2Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 2Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 3Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 4Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 5Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 6Health News:Upcoming Business Seminar at 1Heart Caregiver Services Headquarters Los Angeles California 2
    ... SHANGHAI, China, Jan. 14 /PRNewswire-Asia-FirstCall/ -- China-Biotics, ... Company"), a leading Chinese firm,specializing in the ... products, today announced it has signed contracts,with ... Co., Ltd. ("Yuejia Food"),Shandong Huwa Dairy Industry ...
    ... Released as First Native ApplicationCHARLOTTESVILLE, Va., Jan. 14 ... a leader in knowledge management solutions for healthcare, ... download to Apple(R) iPhone(TM) and iPod(R) touch devices. ... for BlackBerry, Windows Mobile, and Palm OS devices ...
    ... 14 /PRNewswire/ -- Scarguard Labs, LLC, a ... and other dermatological problems through the use of multi-technology ... it has appointed Richard E. Pino as Chief Financial ... accounting, and treasury functions and will report to Chief ...
    ... Transfusion Service Software Confirms its Leading Position in ... Jan. 14 Global Med Technologies(R), Inc. ("Global ... an international e-Health, medical information technology company, today ... EgdeTrack* Transfusion Services Software (marketed as "Hemo Serveur" ...
    ... Number of people sickened in outbreak rises to 425 in ... -- As the number of people sickened by salmonella-contaminated peanut ... said Tuesday that one death in Minnesota and two in ... known for sure that the three people, whose names and ...
    ... Lagan, a provider of enterprise case management solutions that ... announced a new Lagan Human Services Call Center ... agencies in North America. The new solution is ... a range of functions depending on the programs administered, ...
    Cached Medicine News:Health News:China-Biotics, Inc. Signs Agreements With Four Additional Food Manufacturers 2Health News:China-Biotics, Inc. Signs Agreements With Four Additional Food Manufacturers 3Health News:China-Biotics, Inc. Signs Agreements With Four Additional Food Manufacturers 4Health News:Unbound Medicine Announces Download Support for iPhone(TM) and iPod(R) Touch Devices 2Health News:Scarguard Labs, LLC Appoints Richard E. Pino as CFO 2Health News:Global Med Technologies(R)' Inlog Subsidiary Licensed EdgeTrack to 62 French Hospitals in 2008, Including 19 Hospitals in Q4 2008 2Health News:Global Med Technologies(R)' Inlog Subsidiary Licensed EdgeTrack to 62 French Hospitals in 2008, Including 19 Hospitals in Q4 2008 3Health News:Salmonella Linked to Deaths in Virginia, Minnesota 2Health News:Salmonella Linked to Deaths in Virginia, Minnesota 3Health News:Lagan Unveils Human Services Call Center Solution for North America 2
    ... The Elite II features ... proven University of Glasgow,(UG) algorithm. ... criteria to age, the UG,algorithm ... clinically,significant criteria: gender, age, race, ...
    ... face provides three contrast levels (high, 9.5 % ... 20/100. This test is designed to detect very ... contact lens evaluation or due to refractive surgery. ... the same contrast and acuity levels as the ...
    The CSV-1000ETDRS10% test face presents the standard ETDRS test at a contrast level of 10%. This test is widely used in clinical studies for the evaluation of refractive surgery and contact lenses....
    The CSV-1000-1.5CPD is a special test face designed specifically for Food and Drug Administration clinical trials., ,At the recommended test distance of 8 feet, the gratings test one spatial frequenc...
    Medicine Products: